This groundbreaking Theranostic book delivers the definitive roadmap for the next generation of precision oncology by systematically detailing the clinical, regulatory, and drug delivery landscapes of theranostics-the revolutionary integration of therapy and diagnostics-across 20-22 major cancer types. Designed for medical publishers, clinicians, and biotech researchers, this chapter is a structural framework for each malignancy, bridging laboratory breakthroughs in nanotechnology, green nanochemistry, drug delivery, diagnostics, and AI with real-world clinical applications. It serves as an essential commercial and academic asset, offering unprecedented depth on FDA/EMA regulatory hurdles, technology transfer pathways, and actionable data tables that track active clinical trials and global research groups. By addressing key market trends and regulatory challenges, it serves as an essential, multidisciplinary resource for driving personalized oncology and improving patient outcomes
- High-Value Cancer-Specific Market Intel: Analyses the complete theranostic landscape across distinct global cancer markets
- End-to-End Translational Roadmap: Connects cutting-edge nanomedicine, green nanotechnology, nanodiamonds, and AI-driven diagnostics directly to practical FDA/EMA regulatory processes and technology transfer workflows
- Ready-to-Use Clinical & Research Data: Provides a comprehensive reference suite for tracking ongoing clinical trials, preclinical models, patents, and R&D insights
